Related Experiment Videos
The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group
J M Cosset1, M Henry-Amar, J H Meerwaldt
1Institut Gustave Roussy, Villejuif, France.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Prostate cancer brachytherapy: SFRO guidelines 2021.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
[Evaluation and results of ablative therapies in prostate cancer].
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2017
Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study.
Human reproduction (Oxford, England)·2013
Radiological protection in medicine: work of ICRP Committee 3.
Annals of the ICRP·2012
Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC 'boost versus no boost' trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2012
Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns.
European journal of cancer (Oxford, England : 1990)·2026
Thirty years of adjuvant therapy: From treating risk to treating residual disease.
European journal of cancer (Oxford, England : 1990)·2026
Artificial intelligence for brain cancer management: multimodal digital workflows for diagnosis, treatment planning, and longitudinal monitoring.
European journal of cancer (Oxford, England : 1990)·2026
Local therapy to recurrent/metastatic foci augments the benefit of immune checkpoint inhibitors in nasopharyngeal carcinoma.
European journal of cancer (Oxford, England : 1990)·2026
Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer.
European journal of cancer (Oxford, England : 1990)·2026
Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
European journal of cancer (Oxford, England : 1990)·2026
Decision Fatigue and Associated Factors Among Patients with Hematologic Malignancies: Implications for Patient-Centered Decision Support.
Patient preference and adherence·2026